Electrophysiologic effects of intravenous MS-551, a novel class III antiarrhythmic agent, on human atrium and ventricle

Japanese Heart Journal

Volumn 39, Issue 3, 1998, Pages 297-305

  Naitoh, Naoki ^a   Taneda, Koji ^a   Tagawa, Minoru ^a   Furushima, Hiroshi ^a   Yamaura, Masayuki ^a   Aizawa, Yoshifusa ^a  

^a NIIGATA UNIVERSITY   (Japan)

Author keywords

Class III antiarrhythmic agent; MS 551; Refractory period; Reverse use dependency

Indexed keywords

ANTIARRHYTHMIC AGENT; NIFEKALANT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HEART ELECTROPHYSIOLOGY; HEART RIGHT ATRIUM; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; QT INTERVAL; SINUS RHYTHM;

EID: 0031812588     PISSN: 00214868     EISSN: None     Source Type: Journal    
DOI: 10.1536/ihj.39.297     Document Type: Article

References (24)

1. Singh X, Courtney K. On the classification of antiarrhythmic mechanisms: experimental and clinical correlations. In: Zipes DP, Jalife J, editors. Cardiac Electrophysiology: From the Cell to Bedside. Philadelphia, Pa: WB Saunders Co; 1990: 882-97.
2. Singh BAN, Vaughan Williams EM. A third class of antiarrhythmic actions: effects on atrial and ventricular intracellular potentials, and other pharmacologic actions on cardiac muscle, of MJ 1999 and AH3474. Br J Pharmacol 1970; 29: 675-87.
3. Singh BN, Nademanee K. Control of cardiac arrhythmias by selective lengthening of repolarization: theoretic considerations and clinical observations. Am Heart J 1985; 109. 421-30.
4. Vaughan Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 1984; 24: 129-47.
5. Colatsky JJ, Follmer CH, Starmer CF. Channel specificity in antiarrhythmic drug action: mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias. Circulation 1990; 82: 2235-42.
6. Sager TP, Nademanee K, Antimisiaris M, et al. Antiarrhythmic effects of selective prolongation of refractoriness: electrophysiologic actions of sematilide HCL in humans. Circulation 1993; 88: 1072-82.
7. Sager PT, Follmer C, Uppal P, Pruitt C, Godfrey R. The effects of β-adrenergic stimulation on the frequency-dependent electrophysiologic actions of amiodarone and sematilide in humans. Circulation 1994; 90: 1811-9.
8. Argentieri TM, Carroll MS, Sullivan ME. Cellular electrophysiologic effects of the class III antiarrhythmic agents sematilide and clofilium on rabbit atrial tissue. J Cardiovasc Pharmacol 1991; 18: 167-74.
9. Tande PM, Bjornstad H, Yang T, Refsum H. Rate-dependent class III antiarrhythmic action, negative chronotrophy, and positive inotrophy of a novel Ik blocking drug, UK-68, 798: potent in guinea pig but no effect in rat myocardium. J Cardiovasc Pharmacol 1990; 16: 401-10.
10. + current by dofetilide. Circ Res 1993; 72: 75-83.
11. Sedgwick ML, Rasmussen HS, Cobbe SM. Effects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectoris. Am J Cardiol 1992; 70: 1432-7.
12. Katoh H, Ogawa S, Furuno I, Yoh S, Saeki K, Nakamura Y Electrophysiologic effects of E-4031, a class III antiarrhythmic agent, on reentrant ventricular arrhythmias in a canine 7-day-old myocardial infarction model. J Pharmacol Exp Ther 1990; 253: 1077-82.
13. Sanguinetti MC, Jurkiewicz NK, Scott A, Siegl PKS. Isoproterenol antagonizes prolongation of refractory period by the class III antiarrhythmic agent E-4031 in guinea pig myocytes: mechanism of action. Circ Res 1991; 68: 77-84.
14. Buskins SP, Serik CM, Wallace AA, et al. Effects of new and potent methanesulfonilide class III antiarrhythmic agents on myocardial refractoriness and contractility in isolated cardiac muscle. J Cardiovasc Pharmacol 1991; 18: 406-14.
15. Fujiki A, Tani M, Mizumaki K, Shimono M, Inoue H. Electrophysiologic effects of intravenous E-4031, a novel class III antiarrhythmic agent, in patients with supraventricular tachyarrhythmias. J Cardiovasc Pharmacol 1994; 23: 374-8.
16. Katoh R, Ikeda N, Yabek SM, Kannan R, Singh BN. Electrophysiologic effects of the levo- and dextrorotatory isomers of sotalol in isolated cardiac muscle and their in vivo pharmacokinetics. J Am Coll Cardiol 1986; 7: 116-25.
17. Aizawa Y, Niwano S, Chinushi M, et al. Incidence and mechanism of interruption of reentrant ventricular tachycardia with rapid ventricular pacing. Circulation 1992; 85: 589-95.
18. Lee RJ, Leim B, Cohen TJ, Franz MR. Relation between repolarization and refractoriness in the human ventricle: cycle length dependence and effect of procainamide. J Am Coll Cardiol 1992; 19: 614-8.
19. Nattel S, Zeng F-D. Frequency-dependent effects of antiarrhythmic drugs on action potential duration and refractoriness of canine cardiac Purkinje fibers. J Pharmacol Exp Ther 1984; 229: 283-91.
20. Franz MR, Swerdlow CD, Leim BL, Schaefer J. Cycle-length dependence of human action potential duration in vivo: effects of single extrastimuli, sudden sustained rate acceleration and deceleration, and different steady-state frequencies. J Clin Invest 1988; 82: 972-9.
21. Hondeghem LM, Katzung BG. Time- and voltage-dependent interactions of antiarrhythmic drugs with cardiac sodium channels. Biochim Biophys Acta 1977; 472: 373-98.
22. Hondeghem LAM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go: reduced effectiveness and dangers of reverse use dependence. Circulation 1990; 81: 686-90.
23. Scmitt C, Brachmann J, Karch M, et al. Reverse use-dependent effects of sotalol demonstrated by recording monophasic action potentials of the right ventricle. Am J Cardiol 1991; 68: 1183-7.
24. Okada Y, Ogawa S, Sadanaga T, Mitamura H. Assessment of reverse use-dependent blocking actions of class III antiarrhythmic drugs by 24-hour Holter electrocardiography. J Am Coll Cardiol 1996; 27: 84-9.